S&P 500   4,012.92 (+1.05%)
DOW   32,622.30 (+0.70%)
QQQ   311.68 (+1.48%)
AAPL   159.97 (+1.47%)
MSFT   279.59 (+1.58%)
META   204.80 (+2.05%)
GOOGL   101.42 (+0.39%)
AMZN   99.72 (+2.55%)
TSLA   193.41 (+2.23%)
NVDA   269.03 (+1.87%)
NIO   9.90 (+7.61%)
BABA   100.15 (+1.78%)
AMD   95.71 (+1.22%)
T   18.97 (+1.34%)
F   11.94 (+2.93%)
MU   62.93 (+6.16%)
CGC   1.83 (+1.10%)
GE   94.20 (+1.14%)
DIS   96.23 (+1.49%)
AMC   4.94 (-4.08%)
PFE   40.09 (+0.25%)
PYPL   73.87 (+1.61%)
NFLX   330.12 (+2.04%)
S&P 500   4,012.92 (+1.05%)
DOW   32,622.30 (+0.70%)
QQQ   311.68 (+1.48%)
AAPL   159.97 (+1.47%)
MSFT   279.59 (+1.58%)
META   204.80 (+2.05%)
GOOGL   101.42 (+0.39%)
AMZN   99.72 (+2.55%)
TSLA   193.41 (+2.23%)
NVDA   269.03 (+1.87%)
NIO   9.90 (+7.61%)
BABA   100.15 (+1.78%)
AMD   95.71 (+1.22%)
T   18.97 (+1.34%)
F   11.94 (+2.93%)
MU   62.93 (+6.16%)
CGC   1.83 (+1.10%)
GE   94.20 (+1.14%)
DIS   96.23 (+1.49%)
AMC   4.94 (-4.08%)
PFE   40.09 (+0.25%)
PYPL   73.87 (+1.61%)
NFLX   330.12 (+2.04%)
S&P 500   4,012.92 (+1.05%)
DOW   32,622.30 (+0.70%)
QQQ   311.68 (+1.48%)
AAPL   159.97 (+1.47%)
MSFT   279.59 (+1.58%)
META   204.80 (+2.05%)
GOOGL   101.42 (+0.39%)
AMZN   99.72 (+2.55%)
TSLA   193.41 (+2.23%)
NVDA   269.03 (+1.87%)
NIO   9.90 (+7.61%)
BABA   100.15 (+1.78%)
AMD   95.71 (+1.22%)
T   18.97 (+1.34%)
F   11.94 (+2.93%)
MU   62.93 (+6.16%)
CGC   1.83 (+1.10%)
GE   94.20 (+1.14%)
DIS   96.23 (+1.49%)
AMC   4.94 (-4.08%)
PFE   40.09 (+0.25%)
PYPL   73.87 (+1.61%)
NFLX   330.12 (+2.04%)
S&P 500   4,012.92 (+1.05%)
DOW   32,622.30 (+0.70%)
QQQ   311.68 (+1.48%)
AAPL   159.97 (+1.47%)
MSFT   279.59 (+1.58%)
META   204.80 (+2.05%)
GOOGL   101.42 (+0.39%)
AMZN   99.72 (+2.55%)
TSLA   193.41 (+2.23%)
NVDA   269.03 (+1.87%)
NIO   9.90 (+7.61%)
BABA   100.15 (+1.78%)
AMD   95.71 (+1.22%)
T   18.97 (+1.34%)
F   11.94 (+2.93%)
MU   62.93 (+6.16%)
CGC   1.83 (+1.10%)
GE   94.20 (+1.14%)
DIS   96.23 (+1.49%)
AMC   4.94 (-4.08%)
PFE   40.09 (+0.25%)
PYPL   73.87 (+1.61%)
NFLX   330.12 (+2.04%)
NASDAQ:NVCR

NovoCure - NVCR Stock Forecast, Price & News

$58.65
+0.88 (+1.52%)
(As of 03/29/2023 12:27 PM ET)
Add
Compare
Today's Range
$58.01
$58.91
50-Day Range
$56.44
$95.09
52-Week Range
$56.06
$120.03
Volume
145,248 shs
Average Volume
1.06 million shs
Market Capitalization
$6.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.33

NovoCure MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
49.6% Upside
$87.33 Price Target
Short Interest
Healthy
7.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.26mentions of NovoCure in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$24.67 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.65) to ($1.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

399th out of 999 stocks

Surgical & Medical Instruments Industry

41st out of 103 stocks


NVCR stock logo

About NovoCure (NASDAQ:NVCR) Stock

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Stock News Headlines

Kristin Stafford Joins Novocure Board of Directors
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Why NovoCure Stock Is Falling Today
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Why Novocure Stock Is Flying High
Why Novocure Stock Is Skyrocketing Today
Novocure Stock: Bull vs. Bear
Novocure Secures CE Mark for New Array
2 Potentially Explosive Stocks to Buy in November
NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates
Novocure (NVCR) Q3 2022 Earnings Call Transcript
Why Novocure Stock Is Sinking Today
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Company Calendar

Last Earnings
2/23/2023
Today
3/29/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,320
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$87.33
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+48.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-92,530,000.00
Pretax Margin
-15.22%

Debt

Sales & Book Value

Annual Sales
$537.84 million
Book Value
$4.20 per share

Miscellaneous

Free Float
98,896,000
Market Cap
$6.20 billion
Optionable
Optionable
Beta
0.83

Key Executives

  • Asaf DanzigerAsaf Danziger
    Chief Executive Officer & Director
  • Wilhelmus C. M. GroenhuysenWilhelmus C. M. Groenhuysen
    Chief Operating Officer
  • Ashley CordovaAshley Cordova
    Chief Financial Officer
  • Moshe Giladi
    Chief Science Officer
  • Piet Hinoul
    Senior Vice President & Head-Medical













NVCR Stock - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price forecast for 2023?

6 equities research analysts have issued twelve-month price objectives for NovoCure's stock. Their NVCR share price forecasts range from $50.00 to $130.00. On average, they anticipate the company's stock price to reach $87.33 in the next year. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2023?

NovoCure's stock was trading at $73.35 on January 1st, 2023. Since then, NVCR stock has decreased by 21.2% and is now trading at $57.77.
View the best growth stocks for 2023 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, February, 23rd. The medical equipment provider reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.04. The medical equipment provider earned $128.43 million during the quarter, compared to analysts' expectations of $127.20 million. NovoCure had a negative net margin of 17.20% and a negative trailing twelve-month return on equity of 20.98%. The business's quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.25) earnings per share.

What guidance has NovoCure issued on next quarter's earnings?

NovoCure updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $128.40 million-$128.40 million, compared to the consensus revenue estimate of $129.14 million.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nordwand Advisors LLC (8.68%), Baillie Gifford & Co. (8.40%), Price T Rowe Associates Inc. MD (2.07%), Nordwand Advisors LLC (1.44%), Geode Capital Management LLC (1.29%) and Norges Bank (0.93%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $57.77.

How much money does NovoCure make?

NovoCure (NASDAQ:NVCR) has a market capitalization of $6.09 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does NovoCure have?

The company employs 1,320 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.

This page (NASDAQ:NVCR) was last updated on 3/29/2023 by MarketBeat.com Staff